http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 01 Sep 2026 04:23:46 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Ideaya+Biosciences+%28IDYA%29+Reiterated+at+Market+Outperform+by+Citizens+on+IDE849+Advances/27007661.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $42.00 price target on Ideaya Biosciences (NASDAQ: IDYA).</p><p>The analyst commented, "IDEAYA's rapid advancement of IDE849 through the clinic is a strong indicator of the company's conviction in the program. This confidence is supported by findings from Hengrui's ongoing Chinese Phase 1 study, as well as emerging experience from IDYA's own open-label, first-in-Western-humans Phase 1 study, for which data are currently undisclosed. While updated efficacy and durability data from Hengrui at ESMO 2026 and the initial Western dataset in 2H26 remain important catalysts, we view the positive FDA interactions, growing clarity http://www.streetinsider.com/Analyst+Comments/Ideaya+Biosciences+%28IDYA%29+Reiterated+at+Market+Outperform+by+Citizens+on+IDE849+Advances/27007661.html Tue, 01 Sep 2026 04:23:46 -0400 IDYA http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on <chron>August 27, 2026</chron>, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html Fri, 28 Aug 2026 06:00:00 -0400 IDYA O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on <chron>August 27, 2026</chron>, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html Fri, 28 Aug 2026 06:00:00 -0400 IDYA O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on <chron>August 27, 2026</chron>, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html Fri, 28 Aug 2026 06:00:00 -0400 IDYA O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on <chron>August 27, 2026</chron>, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26992254.html Fri, 28 Aug 2026 06:00:00 -0400 IDYA O.28729778 http://www.streetinsider.com/Corporate+News/IDEAYA+and+Genentech+to+test+drug+combo+in+pancreatic+cancer/26946580.html <p>IDEAYA Biosciences (NASDAQ: IDYA) has entered into a clinical collaboration with Genentech, a member of the Roche Group, to evaluate a combination of two investigational drugs in patients with pancreatic ductal adenocarcinoma (PDAC), according to a press release.</p><p>The collaboration will evaluate IDEAYA's IDE892, a Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with Genentech's GDC-7035 (RG6620), a KRAS G12D inhibitor. The trial will target patients whose tumors carry both an MTAP deletion and a KRAS G12D mutation, a combination estimated to occur in up to approximately 15% of PDAC patients.</p><p>Genentech will sponsor the clinical trial and oversee joint governance of the http://www.streetinsider.com/Corporate+News/IDEAYA+and+Genentech+to+test+drug+combo+in+pancreatic+cancer/26946580.html Wed, 19 Aug 2026 06:01:25 -0400 IDYA http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html <div class="xn-content"> <ul type="disc"><li>IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, <span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech's</span> Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma</li><li><span value="ACORN:4015175934" idsrc="xmltag.org" >Genentech</span> will sponsor the clinical trial, and there will be joint governance to oversee the study</li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>Aug. 19, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:IDYA" idsrc="xmltag.org" >IDEAYA Biosciences, Inc.</span> (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it has entered into a clinical collaboration http://www.streetinsider.com/PRNewswire/IDEAYA+Biosciences+Announces+Clinical+Collaboration+with+Genentech+in+MTAP-Deleted+KRAS+G12D-Mutant+Pancreatic+Cancer/26946564.html Wed, 19 Aug 2026 06:00:00 -0400 A.40151759 IDYA O.00050368 O.28729778 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IDEAYA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+BAKER+BROS.+ADVISORS+LP/26929948.html si-local-file:///var/storage/secattach/20260814/26929948.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IDEAYA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+BAKER+BROS.+ADVISORS+LP/26929948.html Fri, 14 Aug 2026 16:03:00 -0400 IDYA O.28729778 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IDEAYA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+BAKER+BROS.+ADVISORS+LP/26929948.html si-local-file:///var/storage/secattach/20260814/26929948.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IDEAYA+Biosciences%2C+Inc.+++++++++++++++Filed+by%3A+BAKER+BROS.+ADVISORS+LP/26929948.html Fri, 14 Aug 2026 16:03:00 -0400 IDYA O.28729778 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Jun+30/26866189.html si-local-file:///var/storage/secattach/20260804/26866189.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Jun+30/26866189.html Tue, 04 Aug 2026 16:06:00 -0400 IDYA O.28729778 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Jun+30/26866189.html si-local-file:///var/storage/secattach/20260804/26866189.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Jun+30/26866189.html Tue, 04 Aug 2026 16:06:00 -0400 IDYA O.28729778 http://www.streetinsider.com/Earnings/IDEAYA+Biosciences+%28IDYA%29+Misses+Q2+EPS+by+16c/26860905.html <p>IDEAYA Biosciences (NASDAQ: IDYA) reported Q2 EPS of ($1.22), $0.16 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $8.86 million versus the consensus estimate of $7.99 million.</p><p>For earnings history and earnings-related data on IDEAYA Biosciences (IDYA) <a href="http://www.streetinsider.com/ec_earnings.php?q=IDYA">click here</a>.</p> http://www.streetinsider.com/Earnings/IDEAYA+Biosciences+%28IDYA%29+Misses+Q2+EPS+by+16c/26860905.html Tue, 04 Aug 2026 06:19:59 -0400 IDYA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Aug+04/26860798.html si-local-file:///var/storage/secattach/20260804/26860798.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Aug+04/26860798.html Tue, 04 Aug 2026 06:05:00 -0400 IDYA O.28729778 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Aug+04/26860798.html si-local-file:///var/storage/secattach/20260804/26860798.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IDEAYA+Biosciences%2C+Inc.++For%3A+Aug+04/26860798.html Tue, 04 Aug 2026 06:05:00 -0400 IDYA O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html <div class="xn-content"> <ul type="disc"><li>Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026</li><li>Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient subset) and Phase 2 OptimUM-09 trial (neoadjuvant primary UM) to be presented at ESMO</li><li>Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) in small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) patients to be presented at ESMO </li><li>Announced clinical collaboration with Roche to evaluate IDE892 (PRMT5) in combination with RG6505 (pan-RAS) http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html Tue, 04 Aug 2026 06:00:00 -0400 A.06822034 A.40820155 A.50216726 IDYA O.00321730 O.20026344 O.21612337 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html <div class="xn-content"> <ul type="disc"><li>Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026</li><li>Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient subset) and Phase 2 OptimUM-09 trial (neoadjuvant primary UM) to be presented at ESMO</li><li>Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) in small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) patients to be presented at ESMO </li><li>Announced clinical collaboration with Roche to evaluate IDE892 (PRMT5) in combination with RG6505 (pan-RAS) http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html Tue, 04 Aug 2026 06:00:00 -0400 A.06822034 A.40820155 A.50216726 IDYA O.00321730 O.20026344 O.21612337 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html <div class="xn-content"> <ul type="disc"><li>Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026</li><li>Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient subset) and Phase 2 OptimUM-09 trial (neoadjuvant primary UM) to be presented at ESMO</li><li>Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) in small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) patients to be presented at ESMO </li><li>Announced clinical collaboration with Roche to evaluate IDE892 (PRMT5) in combination with RG6505 (pan-RAS) http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html Tue, 04 Aug 2026 06:00:00 -0400 A.06822034 A.40820155 A.50216726 IDYA O.00321730 O.20026344 O.21612337 O.28729778 http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html <div class="xn-content"> <ul type="disc"><li>Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026</li><li>Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient subset) and Phase 2 OptimUM-09 trial (neoadjuvant primary UM) to be presented at ESMO</li><li>Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) in small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) patients to be presented at ESMO </li><li>Announced clinical collaboration with Roche to evaluate IDE892 (PRMT5) in combination with RG6505 (pan-RAS) http://www.streetinsider.com/Press+Releases/IDEAYA+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26860443.html Tue, 04 Aug 2026 06:00:00 -0400 A.06822034 A.40820155 A.50216726 IDYA O.00321730 O.20026344 O.21612337 O.28729778